IP considerations arising from increased micro mobility competition

​
June 24, 2022

Following the Queen's Speech, and years of consultations and lobbying from the micro mobility sector, it looks like the e-scooter industry is in for a bumper year. The vehicles have until now been legal to buy, yet illegal to use on the UK's public roads except through authorised ride sharing schemes. However, this will now change through the creation of a new vehicle class for e-scooters specifically.

This is a positive development for the micro mobility sector overall, which in all likelihood will see an increased number of players vying for market share. Emerging start-ups will feel more confident to develop and launch innovative models and accessories, while already established sellers and the companies running ride sharing schemes will see it as an opportunity to quickly expand into what is already a substantial market.

An important aspect of this development, which must not be overlooked, is the role played by intellectual property (IP), and particularly patent and design protection, in how new and established companies shape the e-scooter market. Smaller players face an intense period of balancing the need to quickly grab market share, often using existing technologies, and the need to innovate. Elsewhere, more seasoned companies will want to protect themselves from edgy newcomers.

Pre-emptive entrants

The importance of carefully managing risks posed by third parties' existing patents cannot be underestimated for e-scooter start-ups. Innovators will be monitored by established companies looking to outcompete them and cannot afford any costly and time-consuming legal proceedings resulting from accusations of infringement. While some companies have these capabilities within their team, many will need support from the legal sector to ensure they are covered.

So, first and foremost, start-ups will be looking to confirm that they have Freedom to Operate (FTO). In other words, they will be checking that the products they want to launch in the UK will not infringe other companies' patents. Potentially infringing activities include making, selling, importing and storing infringing articles in the UK. All manner of aspects of scooters are subject to patent protection, such as folding mechanisms (see GB2589813) and accessory mounting devices (see GB2591202). Given patent rights are territorial, most will initially only have to focus on the UK, but companies looking to launch across many markets will face a more complex process of ensuring their FTO across territories.

Another factor to be considered is the future impact of invisible pending patent applications, resulting from the fact that patent applications are only published about 18 months after being submitted to the patent office. Given that the liberalisation of the market will have been foreseen by many, and that established players are already benefitting from the rapid growth in demand for e-scooters, there are likely to be many such applications submitted within the past year or so that are working their way through the patent examination system. Potential future costs of having to license a patent that is not yet enforceable at the time of a product launch need to be taken into account by new entrants. Having to modify products over time to avoid infringing patents is also more common than some might think. Key to success will be performing additional FTO checks periodically, primarily before, but also after, product launch.

Although less pressing that checking the FTO position, particularly if budgets are tight, innovative new entrants should at least consider patenting inventions in their products. Among the variety of benefits of having a patent portfolio is the "bargaining chip" they offer in case of a dispute with another patent holder. For example, if a patent infringement risk is identified by a new player, it might be possible to get the patent holder's permission to use their patented technology by granting them a cross-licence to something in the new player's own portfolio.

Many e-scooter companies will also look into registered design protection. This protects the appearance of a product, rather than its technical workings. For many companies whose differentiation will be largely tied to the design rather than the technical components of an e-scooter, registering designs might be the primary way to have enforceable protection against others, particularly copycats.

Defensive giants

While established e-scooter vendors will have more experience and access to extensive support than start-ups, we are all entering an era where assertive patenting will play an increasingly important role in defending market share. Existing market players need to ensure that any unique features of their products are protected against bullish newcomers. In other words, we can expect an intensification in the pursuit of patents, which needs to be monitored carefully.

In the short term, the fact that patents can only be enforced once they have been granted will mean that many companies with pending patent applications will do what they can to speed up their ongoing application processes, so that they can take action against infringers quickly if necessary. Another road many will go down, and which start-ups need to be alert to, is to monitor the new competition very closely and strategically broaden or split their pending applications to try and widen their reach before they are granted. Both approaches could hurt start-ups that have developed products or business models that are very similar to those of already established companies.

The pressure is on

This is an exciting time for anyone active in the micro mobility market, and it will be interesting to see what will come out of the e-scooter space following the Government's recent announcements. There are lots of causes for optimism for start-ups looking to make their mark, but the pressure is on for them to not only design and market their products innovatively but also to ensure they avoid potential legal pitfalls. In a few years' time, companies that rise to this challenge will be the ones reaping long-term success.

This article was first published in Startups Magazine.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​